Universidad Peruana Cayetano Heredia

Management of oligometastatic disease in soft tissue sarcomas

Mostrar el registro sencillo del ítem

dc.contributor.author Gonzalez, Marcos Roberto
dc.contributor.author Inchaustegui Rivasplata, María Lucía
dc.contributor.author Ruiz Arellanos, Kim Indira
dc.contributor.author de Souza, FF
dc.contributor.author Subhawong, TK
dc.contributor.author Pretell-Mazzini, J
dc.date.accessioned 2023-07-18T16:18:56Z
dc.date.available 2023-07-18T16:18:56Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/13926
dc.description.abstract Oligometastatic soft tissue sarcoma represents an intermediate state between localized and disseminated disease. Combination A combination of surgery, radiotherapy and systemic treatment significantly improves prognosis, with a 5-year overall survival as high as 50%. Due to the high prevalence of lung metastases, most of the surgical evidence is centered around lung metastasectomy. The decision to perform surgical metastasectomy remains dependent on optimal patient selection. Adequate post- surgical lung function, absence of extrapulmonary metastases, control of the primary tumor, and feasibility of achieving negative margins are major criteria for patients to undergo successful surgery. Adequate margins, longer disease-free interval, unilateral, limited number (= 2), metachronous and small (< 2 cm) pulmonary metastasis are some factors associated with improved survival. Radiotherapy, especially SBRT, is an effective treatment for disease control, and its use as (neo)-adjuvant therapy has shown promising results. However, studies comparing radiotherapy against surgery are missing and the efficacy of radiotherapy independent of surgery is not yet clear. Interventional radiology techniques such as percutaneous thermal ablation (PTA) or arterial embolization have also been described as potential treatment alternatives in candidates deemed not fit for surgery. Systemic treatment has traditionally consisted of an anthracycline (doxorubicin)-based regimen with the addition of ifosfamide in certain cases. Recent advances in systemic treatment include the use of targeted therapy and immunotherapy in (oligo)-metastatic STS. However, except for certain histologies, most STS subtypes are chemoresistant, and the response to systemic treatment is poor. en_US
dc.language.iso eng
dc.publisher OAE Publishing
dc.relation.ispartofseries Journal of Cancer Metastasis and Treatment
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Soft tissue sarcoma en_US
dc.subject Oligometastasis en_US
dc.subject Surgery en_US
dc.subject Treatment en_US
dc.subject.mesh Sarcoma
dc.subject.mesh Metástasis de la Neoplasia
dc.subject.mesh Cirugía General
dc.subject.mesh Terapéutica
dc.title Management of oligometastatic disease in soft tissue sarcomas en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.20517/2394-4722.2022.132
dc.relation.issn 2454-2857


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas